PD-L1 expression in medulloblastoma: an evaluation by subgroup
Allison Martin(Albert Einstein College of Medicine), Michael Lim(Stanford University), Alan K. Meeker(Johns Hopkins University), Lisa Sullivan(The University of Texas Southwestern Medical Center), Charles G. Drake(Columbia University Irving Medical Center), Janis M. Taube(Bloomberg (United States)), Daniel Martínez(Children's Hospital of Philadelphia), Eric H. Raabe(Johns Hopkins University), Kenneth J. Cohen(Hospital for Sick Children), Thomas R. Nirschl(Johns Hopkins University), Mariarita Santi(Children's Hospital of Philadelphia), Christopher J. Nirschl(C4 Therapeutics (United States)), Drew M. Pardoll(Bloomberg (United States)), Aleksandra Ogurtsova(Johns Hopkins University), Jillian Phallen(Johns Hopkins University), William R. Bell(Indiana University School of Medicine), Jessica Hicks(Johns Hopkins University), Sarah Harris‐Bookman(Johns Hopkins University), Haiying Xu(Johns Hopkins University), Magda J. Polanczyk(Sidney Kimmel Cancer Center), Peter C. Burger, Charles G. Eberhart(Johns Hopkins University)
Cited by 64
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k